Tanvex Takes A Hit On Trastuzumab With CRL In US

Filing For Herceptin Biosimilar Is Knocked Back By FDA

 
• By Dave Wallace
  
Tanvex has received a CRL for trastuzumab (Shutterstock)

More from Biosimilars

More from Generics Bulletin